| Literature DB >> 26561805 |
Taku Kaitsuka1, Kazuhito Tomizawa2.
Abstract
Protein transduction using cell-penetrating peptides (CPPs) is useful for the delivery of large protein molecules, including some transcription factors. This method is safer than gene transfection methods with a viral vector because there is no risk of genomic integration of the exogenous DNA. Recently, this method was reported as a means for the induction of induced pluripotent stem (iPS) cells, directing the differentiation into specific cell types and supporting gene editing/correction. Furthermore, we developed a direct differentiation method to obtain a pancreatic lineage from mouse and human pluripotent stem cells via the protein transduction of three transcription factors, Pdx1, NeuroD, and MafA. Here, we discuss the possibility of using CPPs as a means of directing the differentiation of iPS cells and other stem cell technologies.Entities:
Keywords: cell-penetrating peptide; induced pluripotent stem cell; pancreatic differentiation; poly-arginine; protein transduction
Mesh:
Substances:
Year: 2015 PMID: 26561805 PMCID: PMC4661845 DOI: 10.3390/ijms161125986
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1CPP-mediated protein transduction technologies in reprogramming, gene editing/correction, and differentiation of iPS cells. CPP-mediated protein transduction methods are used for key steps in iPS cell technologies. The reprogramming of somatic cells is induced with Yamanaka-4 factors fused to CPPs. Gene correction of disease-specific mutation is performed by the CRISPR-Cas9 system with CPP-fused Cas9 endonuclease. The differentiation of iPS cells is directed with CPP-fused transcription factors. OSKM, Oct4, Sox2, Klf4, c-Myc; TF, transcription factor.
Figure 2Protein transduction into human iPS cells. Human iPS cells of 201B7 were treated with EGFP or 9R-EGFP for 6 h at a final concentration of 1 µM and GFP fluorescence was analyzed by confocal microscopy. (A–C) EGFP-treated cells. Images of EGFP fluorescence (A); DIC (B) and their merge (C) were shown. (D–F) EGFP-9R-treated cells. Images of EGFP fluorescence (D); DIC (E) and their merge (F) were shown; (G) Magnified image of indicated area by white box in (D). GFP fluorescence was detected in the cytoplasm and cell membrane. Scale bars are 100 µm. 9R, nine arginines. DIC, differential interference contrast.
Figure 3Scheme of the protocol for pancreatic differentiation with Pdx1, NeuroD and MafA-11R protein transduction. Dissociated mouse ES or iPS cells were plated at day 0 and directed to pancreatic differentiation in medium supplemented with Activin A (ActA) and basic fibroblast growth factor (bFGF) from days 1 to 7, followed by medium supplemented with fibroblast growth factor 10 (FGF10), KAAD-cyclopamine (CYC), and retinoic acid (RA) from day 7 to 11, and medium supplemented with nicotinamide (NAM) and glucagon-like peptide-1 (GLP-1) from day 11 to 17. At day 17, a part of differentiated cells express insulin and mature pancreatic β-cell markers. Blue boxes show recombinant proteins of Pdx1, NeuroD, and MafA-11R and these proteins were added at the indicated time-points. d: day; 11R: 11 arginine.
Summary of pluripotent stem cell technologies via protein transduction methods.
| CPPs | Proteins | Supplements | Technologies | Cell Types | References |
|---|---|---|---|---|---|
| Poly-arginine | OSKM | NA | Reprogramming | MEFs | [ |
| Poly-arginine | OSKM | NA | Reprogramming | HNFs | [ |
| NA | ES cell-derived extract proteins | Streptolysin O | Reprogramming | Mouse cardiac fibroblasts | [ |
| Hydrophobic MTDs | OSKMN or OSKML | NA | Partial reprogramming | HDFs | [ |
| TAT | Cre | NA | Recombination | Mouse ES cells | [ |
| TAT | Cre | NA | Recombination | Human ES cells | [ |
| TAT | FLP | dTAT-HA2 peptide | Recombination | Mouse or human ES cells | [ |
| Poly-arginine | Cas9 and sgRNA | NA | Gene disruption | Human ES cells | [ |
| NA | Cre or Cas9 | Hypertonic solution and NDSB-201 | Gene editing | Mouse or human ES cells | [ |
| NA | Cre, TALE or Cas9 | Anionic proteins and cationic lipids | Gene editing | Mouse ES cells | [ |
| PTDs or Poly-arginine | Pdx1, NeuroD and MafA | NA | Pancreatic differentiation | Mouse ES cells or human iPS cells | [ |
| TAT | Nkx2.2 | NA | Neural differentiation | Mouse NSCs | [ |
| TAT | Pax6 | NA | Neural differentiation | Rat NSCs | [ |
CPP, cell-penetrating peptide; ES, embryonic stem; HDF, human dermal fibroblasts; HNF, human newborn fibroblast; iPS, induced pluripotent stem; MEF, mouse embryonic fibroblast; MTD, macromolecule transduction domain; NA, not applicable; NSC, neural stem cells; OSKM, Oct-4, Sox2, Klf4, c-Myc; OSKMN, Oct-4, Sox2, Klf4, c-Myc, Nanog; OSKML, Oct-4, Sox2, Klf4, c-Myc, Lin28; PTD, protein transduction domain; sgRNA, single-guide RNA; TAT, trans-activator of transcription.